Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$10.58 - $17.9 $29,624 - $50,119
2,800 New
2,800 $30,000
Q4 2023

Feb 14, 2024

BUY
$17.1 - $22.26 $220,590 - $287,154
12,900 Added 176.71%
20,200 $437,000
Q3 2023

Nov 14, 2023

SELL
$16.75 - $48.98 $85,425 - $249,797
-5,100 Reduced 41.13%
7,300 $150,000
Q2 2023

Aug 14, 2023

BUY
$40.65 - $59.54 $504,060 - $738,296
12,400 New
12,400 $583,000
Q4 2022

Feb 14, 2023

SELL
$32.2 - $43.61 $77,280 - $104,664
-2,400 Reduced 42.86%
3,200 $122,000
Q3 2022

Nov 14, 2022

BUY
$32.28 - $43.27 $180,768 - $242,312
5,600 New
5,600 $219,000
Q4 2019

Feb 14, 2020

SELL
$60.18 - $154.77 $1.25 Million - $3.22 Million
-20,800 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$140.29 - $189.96 $2.92 Million - $3.95 Million
20,800 New
20,800 $2.92 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $326M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.